Global Corticosteroids Inhalation Formulation Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Corticosteroids Inhalation Formulation market size was valued at US$ 20690 million in 2024 and is forecast to a readjusted size of USD 33120 million by 2031 with a CAGR of 7.0% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Corticosteroid inhalation formulations are a cornerstone in the long-term management of asthma and chronic obstructive pulmonary disease (COPD), aiming to control inflammation in the airways. These formulations deliver corticosteroids directly to the lungs, minimizing systemic absorption and reducing the risk of side effects compared to oral steroids. By reducing inflammation, corticosteroids help prevent asthma attacks and improve lung function. Inhalation devices like metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers are commonly used to administer these medications. Advances in inhaler technology have enhanced the precision and efficiency of drug delivery, improving patient adherence and overall disease control. Combination inhalers that pair corticosteroids with bronchodilators are also widely used, providing both anti-inflammatory and bronchodilatory effects in a single formulation.
This report is a detailed and comprehensive analysis for global Corticosteroids Inhalation Formulation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Corticosteroids Inhalation Formulation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Corticosteroids Inhalation Formulation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Corticosteroids Inhalation Formulation market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm AB, GSK, AstraZeneca, Novartis, Teva Respiratory, Boehringer Ingelheim International, Cipla, Merck, Lupin, Perrigo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Corticosteroids Inhalation Formulation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Fluticasone
Budesonide
Mometasone Furoate
Beclomethasone
Other
Market segment by Application
Hospitals
Specialty Clinics
Retail Pharmacy Chains
Online Pharmacies
Other
Major players covered
Recipharm AB
GSK
AstraZeneca
Novartis
Teva Respiratory
Boehringer Ingelheim International
Cipla
Merck
Lupin
Perrigo
Viatris
Organon Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Corticosteroids Inhalation Formulation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Corticosteroids Inhalation Formulation, with price, sales quantity, revenue, and global market share of Corticosteroids Inhalation Formulation from 2020 to 2025.
Chapter 3, the Corticosteroids Inhalation Formulation competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Corticosteroids Inhalation Formulation breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Corticosteroids Inhalation Formulation market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Corticosteroids Inhalation Formulation.
Chapter 14 and 15, to describe Corticosteroids Inhalation Formulation sales channel, distributors, customers, research findings and conclusion.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Corticosteroid inhalation formulations are a cornerstone in the long-term management of asthma and chronic obstructive pulmonary disease (COPD), aiming to control inflammation in the airways. These formulations deliver corticosteroids directly to the lungs, minimizing systemic absorption and reducing the risk of side effects compared to oral steroids. By reducing inflammation, corticosteroids help prevent asthma attacks and improve lung function. Inhalation devices like metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers are commonly used to administer these medications. Advances in inhaler technology have enhanced the precision and efficiency of drug delivery, improving patient adherence and overall disease control. Combination inhalers that pair corticosteroids with bronchodilators are also widely used, providing both anti-inflammatory and bronchodilatory effects in a single formulation.
This report is a detailed and comprehensive analysis for global Corticosteroids Inhalation Formulation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Corticosteroids Inhalation Formulation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Corticosteroids Inhalation Formulation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Corticosteroids Inhalation Formulation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Corticosteroids Inhalation Formulation market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm AB, GSK, AstraZeneca, Novartis, Teva Respiratory, Boehringer Ingelheim International, Cipla, Merck, Lupin, Perrigo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Corticosteroids Inhalation Formulation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Fluticasone
Budesonide
Mometasone Furoate
Beclomethasone
Other
Market segment by Application
Hospitals
Specialty Clinics
Retail Pharmacy Chains
Online Pharmacies
Other
Major players covered
Recipharm AB
GSK
AstraZeneca
Novartis
Teva Respiratory
Boehringer Ingelheim International
Cipla
Merck
Lupin
Perrigo
Viatris
Organon Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Corticosteroids Inhalation Formulation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Corticosteroids Inhalation Formulation, with price, sales quantity, revenue, and global market share of Corticosteroids Inhalation Formulation from 2020 to 2025.
Chapter 3, the Corticosteroids Inhalation Formulation competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Corticosteroids Inhalation Formulation breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Corticosteroids Inhalation Formulation market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Corticosteroids Inhalation Formulation.
Chapter 14 and 15, to describe Corticosteroids Inhalation Formulation sales channel, distributors, customers, research findings and conclusion.
Table of Contents
114 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Corticosteroids Inhalation Formulation by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
